Engagement of Toll-Like Receptor 3 Induces Vascular Endothelial Growth Factor and Interleukin-8 in Human Rheumatoid Synovial Fibroblasts
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Angiogenesis, which is a critical step in the initiation and progression of rheumatoid arthritis (RA), involves pro-angiogenic factors, including interleukin (IL)-8 and vascular endothelial growth factor (VEGF). We investigated the role of Toll-like receptor 3 (TLR3) in the regulation of pro-angiogenic factors in RA fibroblastlike synoviocytes (FLS). Methods: FLS were isolated from RA synovial tissues and stimulated with the TLR3 ligand, poly (I:C). The levels of VEGF and IL-8 in the culture supernatants were measured using enzyme-linked immunosorbent assays, and the mRNA levels were assessed by semiquantitative reverse transcription-polymerase chain reaction. The expression patterns of VEGF and IL-8 in the RA synovium and osteoarthritis (OA) synovium were compared using immunohistochemistry. Results: The expression levels of TLR3, VEGF, and IL-8 were significantly higher in the RA synovium than in the OA synovium. VEGF and IL-8 production were increased in the culture supernatants of RA FLS stimulated with poly (I:C), and the genes for these proteins were up-regulated at the transcriptional level after poly (I:C) treatment. Treatment with inhibitors of nuclear factor-kappaB (NF-κB), i.e., pyrrolidine dithiocarbamate and parthenolide, abrogated the stimulatory effect of poly (I:C) on the production of VEGF and IL-8 in RA FLS. Conclusions: Our results suggest that the activation of TLR3 in RA FLS promotes the production of proangiogenic factors, in a process that is mediated by the NF-κB signaling pathway. Therefore, targeting the TLR3pathway may be a promising approach to preventing pathologic angiogenesis in RA. (Korean J Intern Med 2010;25:429-435)
Abstract
Background/Aims: Angiogenesis, which is a critical step in the initiation and progression of rheumatoid arthritis (RA), involves pro-angiogenic factors, including interleukin (IL)-8 and vascular endothelial growth factor (VEGF). We investigated the role of Toll-like receptor 3 (TLR3) in the regulation of pro-angiogenic factors in RA fibroblastlike synoviocytes (FLS). Methods: FLS were isolated from RA synovial tissues and stimulated with the TLR3 ligand, poly (I:C). The levels of VEGF and IL-8 in the culture supernatants were measured using enzyme-linked immunosorbent assays, and the mRNA levels were assessed by semiquantitative reverse transcription-polymerase chain reaction. The expression patterns of VEGF and IL-8 in the RA synovium and osteoarthritis (OA) synovium were compared using immunohistochemistry. Results: The expression levels of TLR3, VEGF, and IL-8 were significantly higher in the RA synovium than in the OA synovium. VEGF and IL-8 production were increased in the culture supernatants of RA FLS stimulated with poly (I:C), and the genes for these proteins were up-regulated at the transcriptional level after poly (I:C) treatment. Treatment with inhibitors of nuclear factor-kappaB (NF-κB), i.e., pyrrolidine dithiocarbamate and parthenolide, abrogated the stimulatory effect of poly (I:C) on the production of VEGF and IL-8 in RA FLS. Conclusions: Our results suggest that the activation of TLR3 in RA FLS promotes the production of proangiogenic factors, in a process that is mediated by the NF-κB signaling pathway. Therefore, targeting the TLR3pathway may be a promising approach to preventing pathologic angiogenesis in RA. (Korean J Intern Med 2010;25:429-435)
참고문헌 (30)
- Huang S, "Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma", Am J Pathol, 161, pp.125~134 (2002)
- Mizukami Y, "Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells", Nat Med, 11, pp.992~997 (2005)
- Kim S, "Immuno-modulatory gene polymorphisms and outcome in breast and ovarian cancer", Immunol Invest, 38, pp.324~340 (2009)
- Kasama T, "Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: critical involvement of the interaction with synovial fibroblasts", Arthritis Rheum, 44, pp.2512~2524 (2001)
- Cho ML, "Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts", Arthritis Rheum, 46, pp.1202~1209 (2002)
- Flacher V, "Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria", J Immunol, 177, pp.7959~7967 (2006)
- Takeda K, "Toll-like receptors", Annu Rev Immunol, 21, pp.335~376 (2003)
- Brentano F, "RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3", Arthritis Rheum, 52, pp.2656~2665 (2005)
- Huang Q, "Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis", Arthritis Rheum, 56, pp.2192~2201 (2007)
- Ospelt C, "Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis", Arthritis Rheum, 58, pp.3684~3692 (2008)
- Muzio M, "Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells", J Immunol, 164, pp.5998~6004 (2000)
- Zare F, "Arthritogenic properties of double-stranded (viral) RNA", J Immunol, 172, pp.5656~5663 (2004)
- Kumar MV, "Innate immunity in the retina: Toll-like receptor (TLR) signaling in human retinal pigment epithelial cells", J Neuroimmunol, 153, pp.7~15 (2004)
- Kim HR, "Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways", Rheumatology (Oxford), 46, pp.57~64 (2007)
- Izquierdo E, "Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy", PLoS One, 4, pp.e8131~ (2009)
- Koch AE, "Angiogenesis as a target in rheumatoid arthritis", Ann Rheum Dis, 62, pp.ii60~ii67 (2003)
- Li A, "Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis", Angiogenesis, 8, pp.63~71 (2005)
- Koch AE, "Interleukin-8 as a macrophage-derived mediator of angiogenesis", Science, 258, pp.1798~1801 (1992)
- Masood R, "Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi’s sarcoma", Clin Cancer Res, 7, pp.2693~2702 (2001)
- Li A, "IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis", J Immunol, 170, pp.3369~3376 (2003)
- Huang Q, "Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis", J Leukoc Biol, 88, pp.253~262 (2010)
- Meng L, "Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats", Arthritis Res Ther, 12, pp.R103~ (2010)
- Franssila R, "Infection and musculoskeletal conditions: viral causes of arthritis", Best Pract Res Clin Rheumatol, 20, pp.1139~1157 (2006)
- Bokarewa M, "Arthritogenic dsRNA is present in synovial fluid from rheumatoid arthritis patients with an erosive disease course", Eur J Immunol, 38, pp.3237~3244 (2008)
- Roelofs MF, "Type I interferons might form the link between Toll-like receptor (TLR) 3", 7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA), 2009, pp.68, 1486~1493
- Holm CK, "TLR3 ligand polyinosinic: polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells", J Immunol, 183, pp.4422~4431 (2009)
- Paone A, "Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha", Neoplasia, 12, pp.539~549 (2010)
- Kleinman ME, "Sequence- and targetindependent angiogenesis suppression by siRNA via TLR3", Nature, 452, pp.591~597 (2008)
- Kim KW, "TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis", Immunol Lett, 124, pp.9~17 (2009)
- Finckh A, "Treatment of very early rheumatoid arthritis with symptomatic therapy, diseasemodifying antirheumatic drugs, or biologic agents: a costeffectiveness analysis", Ann Intern Med, 151, pp.612~621 (2009)